Understanding how the Epstein-Barr Virus controls its behavior and links to cancer
Epigenetic Regulation of Epstein-Barr Virus
This study is looking at how the Epstein-Barr Virus (EBV) changes its behavior in different environments, which could help us understand how it might lead to certain cancers, and the findings could eventually help develop new treatments for patients affected by this virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11035160 on NIH RePORTER |
What this research studies
This research investigates the role of epigenetic mechanisms in the Epstein-Barr Virus (EBV), which can lead to various cancers. By examining how EBV adapts its gene expression in different host environments, the study aims to uncover the underlying processes that allow the virus to persist and potentially cause malignancies. The research involves analyzing viral and host DNA modifications, including histone changes and DNA methylation, to understand their impact on viral latency and cancer development. Patients may benefit from insights gained into EBV's behavior, which could lead to new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Epstein-Barr Virus infections, particularly those at risk for related cancers.
Not a fit: Patients without Epstein-Barr Virus infections or those not at risk for EBV-related malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments or preventive measures for cancers associated with Epstein-Barr Virus.
How similar studies have performed: Previous research has shown promising results in understanding viral latency and cancer links, indicating that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Lieberman, Paul M. — Wistar Institute
- Study coordinator: Lieberman, Paul M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.